# Replacing Saturated Fat with Linoleic-Acid-Rich Oils

LA-rich oil replacement reliably changes lipid markers; exact coronary-event benefit needs more careful source and intervention separation, while blanket inflammatory harm and carnivore superiority remain unproved.

The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior.

Clinical and biomarker contexts were tested in different baseline-defined groups, but a positive exact randomized clinical crossing was not verified from accessible primary results. Thus divergent contexts do not themselves promote the exact claim to Ε. Cohort diet replacement models, circulating fatty-acid instruments, high-dose historical foods and hypercaloric muffin studies are labelled individually. No adherent or symptom-benefiting group is defined after outcomes to remove negative results.